Truist Financial Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)

Tip Ranks
2025.12.04 05:55
portai
I'm PortAI, I can summarize articles.

Truist Financial analyst maintained a Buy rating on Fulcrum Therapeutics, with shares closing at $9.06. H.C. Wainwright also issued a Buy rating, while TR | OpenAI reiterated a Hold rating on December 2. The news highlights varying analyst opinions on Fulcrum Therapeutics.

Truist Financial analyst maintained a Buy rating on Fulcrum Therapeutics yesterday. The company’s shares closed yesterday at $9.06.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

In addition to Truist Financial, Fulcrum Therapeutics also received a Buy from H.C. Wainwright’s Andrew Fein in a report issued on November 24. However, on December 2, TR | OpenAI – 4o reiterated a Hold rating on Fulcrum Therapeutics (NASDAQ: FULC).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer